Diabetes Research Institute Foundation Inc is located in Hollywood, FL. The organization was established in 1973. As of 06/2021, Diabetes Research Institute Foundation Inc employed 34 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Diabetes Research Institute Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2021, Diabetes Research Institute Foundation Inc generated $13.9m in total revenue. This represents relatively stable growth, over the past 6 years the organization has increased revenue by an average of 4.1% each year. All expenses for the organization totaled $13.7m during the year ending 06/2021. While expenses have increased by 3.9% per year over the past 6 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
TO PROVIDE THE DIABETES RESEARCH INSTITUTE WITH THE FUNDING TO CURE DIABETES NOW.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE DIABETES RESEARCH INSTITUTE FOUNDATION FUNDS BASIC, PRE-CLINICAL AND PATIENT-BASED RESEARCH STUDIES, INCLUDING FIVE PHASE I/II CLINICAL STUDIES, SEVERAL OF WHICH ARE SIMULTANEOUSLY UNDERWAY AT THE DIABETES RESEARCH INSTITUTE (DRI), WITH THE OTHERS PENDING COMMENCEMENT. THE ONGOING 'ISLETS IN THE OMENTUM' BIOHUB TRIAL WAS THE FIRST STEP IN TESTING THE SAFETY AND EFFICACY OF INSULIN-PRODUCING CELLS TRANSPLANTED WITHIN A TISSUE-ENGINEERED PLATFORM IN A DIFFERENT SITE THAN THE LIVER, THE TRADITIONAL TRANSPLANT SITE. FOUNDATION FUNDING HAS ALLOWED THE DRI'S CLINICAL CELL TRANSPLANT TEAM TO CONTACT AND SCREEN MORE THAN 1,200 CANDIDATES FOR THIS INNOVATIVE PILOT TRIAL, SEVERAL OF WHOM WERE SELECTED AND PLACED ON THE WAITING LIST TO UNDERGO THE PROCEDURE PENDING THE AVAILABILITY OF A MATCHING DONOR ORGAN. OTHER ALTERNATIVE TRANSPLANT SITES CONTINUE TO BE EXPLORED. DRIF FUNDING ALSO SUPPORTS THE CONTINUED FOLLOW-UP AND CARE OF THE DRI'S ISLET TRANSPLANT PATIENTS WHO HAVE PARTICIPATED IN PREVIOUS CLINICAL TRIALS. MANY OF THESE HAVE REMAINED INSULIN INDEPENDENT FOR A VARYING NUMBER OF YEARS. THIS PAST YEAR, DRI PRESENTED DATA SHOWING THAT THEIR ISLET TRANSPLANT PATIENTS WHO WERE STILL FREE FROM INSULIN FOR AN AVERAGE OF 10 YEARS HAD NEAR-NORMAL BLOOD SUGAR LEVELS, SIMILAR TO THOSE WITHOUT DIABETES. DRIF HAS ALSO FUNDED DRI RESEARCH PROJECTS THAT FOCUS ON ESTABLISHING IMMUNE TOLERANCE AND REVERSING AUTOIMMUNITY, THE BODY'S DESTRUCTION OF THE INSULIN-PRODUCING CELLS WHICH CAUSED THE ONSET OF THE DISEASE. SEVERAL OF THE CLINICAL TRIALS ADDRESS THESE CHALLENGES WHILE OTHER RESEARCH EARLIER IN THE PIPELINE REMAINS UNDERWAY. ANOTHER MAJOR RESEARCH AREA THAT DRIF SUPPORTS IS THE DEVELOPMENT OF AN UNLIMITED SUPPLY OF INSULIN-PRODUCING CELLS. DRIF-FUNDED STUDIES HAVE LED TO SIGNIFICANT PROGRESS IN STIMULATING THE REGENERATION OF PANCREATIC STEM CELLS INTO INSULIN-PRODUCING CELLS USING A SINGLE FDA-APPROVED MOLECULE. THIS SIGNIFICANT FINDING OPENS TO DOOR TO A NATURAL CELL SUPPLY BANK WITHIN THE PATIENT'S BODY, ADDRESSING SEVERAL ONGOING CHALLENGES FOR CURING THE DISEASE. THE DRIF HAS FUNDED INTERNATIONAL RESEARCHER TRAINING AND KEY COLLABORATIVE PROGRAMS THAT HELP ACCELERATE RESEARCH PROGRESS THROUGH THE SHARING OF IDEAS AND ADVANCEMENTS. ALSO, DRIF-FUNDED RESEARCH EQUIPMENT WAS USED IN A PHASE III MULTI-CENTER CLINICAL ISLET TRANSPLANTATION TRIAL. THE RESULTING DATA DEMONSTRATED THAT ISLET TRANSPLANTATION IS EFFECTIVE IN PREVENTING SEVERE HYPOGLYCEMIA - DANGEROUSLY LOW BLOOD SUGAR LEVELS - WHICH REPRESENTS A PARTICULARLY FEARED COMPLICATION IN TYPE 1 DIABETES THAT CAN LEAD TO SEIZURES, LOSS OF CONSCIOUSNESS AND EVEN DEATH. IMPORTANTLY, THE RESULTS OF THIS PHASE III TRIAL PAVE THE WAY FOR ISLET TRANSPLANTATION TO BECOME AN FDA-AUTHORIZED TREATMENT FOR PATIENTS WITH DIABETES AND ONE THAT WOULD BE ELIGIBLE FOR INSURANCE REIMBURSEMENT. KEY FUNDED RESEARCH AREAS INCLUDE CELL-BASED THERAPIES FOR ISLET REPLACEMENT, IMMUNE TOLERANCE, IMMUNE REGULATION, REGENERATIVE MEDICINE, AND STEM CELL RESEARCH, AMONG OTHERS, TO RESTORE BIOLOGICAL INSULIN PRODUCTION. TOGETHER WITH OTHER DIABETES ADVOCACY ORGANIZATIONS, THE DRIF HAS APPEARED BEFORE CONGRESS TO REQUEST INCREASED FUNDING FOR DIABETES RESEARCH, AND HAS MADE RECOMMENDATIONS ON THE FUTURE DIRECTION OF RESEARCH APPROPRIATIONS. DRIF ALSO HOSTS AND PARTICIPATES IN A VARIETY OF INFORMATIONAL WORKSHOPS FOR PEOPLE WITH DIABETES AND THEIR FAMILIES FOCUSING ON THE LATEST ADVANCES TOWARD A CURE AND THE NEWEST DIABETES MANAGEMENT TECHNIQUES. THROUGH ITS WEBSITE DIABETESRESEARCH.ORG, THE DRIF PROVIDES 'NEWS YOU CAN USERESEARCH UPDATES FOR THOSE LIVING WITH DIABETES AND THEIR FAMILY MEMBERS IN THE FORM OF E-NEWSLETTERS, VIDEOS, EMAIL ANNOUNCEMENTS AND INFORMATION VIA SOCIAL MEDIA.
COMMUNITY DIABETES EDUCATION. THE DIABETES RESEARCH INSTITUTE FOUNDATION PROVIDES INFORMATION TO THE PUBLIC VIA ITS WEBSITE LITERATURE, SPEAKERS AND HOSTING AN ANNUAL DIABETES RESEARCH CONFERENCE, PRINT INTERVIEWS AND TOLL FREE NUMBER 800-321-3437. THE PUBLIC GAINS KNOWLEDGE ABOUT DIABETES, DIABETES CARE AND RESEARCH TOWARDS FINDING A CURE FOR DIABETES.
THE DIABETES RESEARCH INSTITUTE FOUNDATION FUNDS BASIC, PRE-CLINICAL AND PATIENT-BASED RESEARCH STUDIES, INCLUDING FIVE PHASE I/II CLINICAL STUDIES, SEVERAL OF WHICH ARE SIMULTANEOUSLY UNDERWAY AT THE DIABETES RESEARCH INSTITUTE (DRI), WITH THE OTHERS PENDING COMMENCEMENT. THE ONGOING 'ISLETS IN THE OMENTUM' BIOHUB TRIAL WAS THE FIRST STEP IN TESTING THE SAFETY AND EFFICACY OF INSULIN-PRODUCING CELLS TRANSPLANTED WITHIN A TISSUE-ENGINEERED PLATFORM IN A DIFFERENT SITE THAN THE LIVER, THE TRADITIONAL TRANSPLANT SITE. FOUNDATION FUNDING HAS ALLOWED THE DRI'S CLINICAL CELL TRANSPLANT TEAM TO CONTACT AND SCREEN MORE THAN 1,200 CANDIDATES FOR THIS INNOVATIVE PILOT TRIAL, SEVERAL OF WHOM WERE SELECTED AND PLACED ON THE WAITING LIST TO UNDERGO THE PROCEDURE PENDING THE AVAILABILITY OF A MATCHING DONOR ORGAN. OTHER ALTERNATIVE TRANSPLANT SITES CONTINUE TO BE EXPLORED. DRIF FUNDING ALSO SUPPORTS THE CONTINUED FOLLOW-UP AND CARE OF THE DRI'S ISLET TRANSPLANT PATIENTS WHO HAVE PARTICIPATED IN PREVIOUS CLINICAL TRIALS. MANY OF THESE HAVE REMAINED INSULIN INDEPENDENT FOR A VARYING NUMBER OF YEARS. THIS PAST YEAR, DRI PRESENTED DATA SHOWING THAT THEIR ISLET TRANSPLANT PATIENTS WHO WERE STILL FREE FROM INSULIN FOR AN AVERAGE OF 10 YEARS HAD NEAR-NORMAL BLOOD SUGAR LEVELS, SIMILAR TO THOSE WITHOUT DIABETES. DRIF HAS ALSO FUNDED DRI RESEARCH PROJECTS THAT FOCUS ON ESTABLISHING IMMUNE TOLERANCE AND REVERSING AUTOIMMUNITY, THE BODY'S DESTRUCTION OF THE INSULIN-PRODUCING CELLS WHICH CAUSED THE ONSET OF THE DISEASE. SEVERAL OF THE CLINICAL TRIALS ADDRESS THESE CHALLENGES WHILE OTHER RESEARCH EARLIER IN THE PIPELINE REMAINS UNDERWAY. ANOTHER MAJOR RESEARCH AREA THAT DRIF SUPPORTS IS THE DEVELOPMENT OF AN UNLIMITED SUPPLY OF INSULIN-PRODUCING CELLS. DRIF-FUNDED STUDIES HAVE LED TO SIGNIFICANT PROGRESS IN STIMULATING THE REGENERATION OF PANCREATIC STEM CELLS INTO INSULIN-PRODUCING CELLS USING A SINGLE FDA-APPROVED MOLECULE. THIS SIGNIFICANT FINDING OPENS TO DOOR TO A NATURAL CELL SUPPLY BANK WITHIN THE PATIENT'S BODY, ADDRESSING SEVERAL ONGOING CHALLENGES FOR CURING THE DISEASE. THE DRIF HAS FUNDED INTERNATIONAL RESEARCHER TRAINING AND KEY COLLABORATIVE PROGRAMS THAT HELP ACCELERATE RESEARCH PROGRESS THROUGH THE SHARING OF IDEAS AND ADVANCEMENTS. ALSO, DRIF-FUNDED RESEARCH EQUIPMENT WAS USED IN A PHASE III MULTI-CENTER CLINICAL ISLET TRANSPLANTATION TRIAL. THE RESULTING DATA DEMONSTRATED THAT ISLET TRANSPLANTATION IS EFFECTIVE IN PREVENTING SEVERE HYPOGLYCEMIA - DANGEROUSLY LOW BLOOD SUGAR LEVELS - WHICH REPRESENTS A PARTICULARLY FEARED COMPLICATION IN TYPE 1 DIABETES THAT CAN LEAD TO SEIZURES, LOSS OF CONSCIOUSNESS AND EVEN DEATH. IMPORTANTLY, THE RESULTS OF THIS PHASE III TRIAL PAVE THE WAY FOR ISLET TRANSPLANTATION TO BECOME AN FDA-AUTHORIZED TREATMENT FOR PATIENTS WITH DIABETES AND ONE THAT WOULD BE ELIGIBLE FOR INSURANCE REIMBURSEMENT. KEY FUNDED RESEARCH AREAS INCLUDE CELL-BASED THERAPIES FOR ISLET REPLACEMENT, IMMUNE TOLERANCE, IMMUNE REGULATION, REGENERATIVE MEDICINE, AND STEM CELL RESEARCH, AMONG OTHERS, TO RESTORE BIOLOGICAL INSULIN PRODUCTION. TOGETHER WITH OTHER DIABETES ADVOCACY ORGANIZATIONS, THE DRIF HAS APPEARED BEFORE CONGRESS TO REQUEST INCREASED FUNDING FOR DIABETES RESEARCH, AND HAS MADE RECOMMENDATIONS ON THE FUTURE DIRECTION OF RESEARCH APPROPRIATIONS. DRIF ALSO HOSTS AND PARTICIPATES IN A VARIETY OF INFORMATIONAL WORKSHOPS FOR PEOPLE WITH DIABETES AND THEIR FAMILIES FOCUSING ON THE LATEST ADVANCES TOWARD A CURE AND THE NEWEST DIABETES MANAGEMENT TECHNIQUES. THROUGH ITS WEBSITE DIABETESRESEARCH.ORG, THE DRIF PROVIDES 'NEWS YOU CAN USERESEARCH UPDATES FOR THOSE LIVING WITH DIABETES AND THEIR FAMILY MEMBERS IN THE FORM OF E-NEWSLETTERS, VIDEOS, EMAIL ANNOUNCEMENTS AND INFORMATION VIA SOCIAL MEDIA.
COMMUNITY DIABETES EDUCATION. THE DIABETES RESEARCH INSTITUTE FOUNDATION PROVIDES INFORMATION TO THE PUBLIC VIA ITS WEBSITE LITERATURE, SPEAKERS AND HOSTING AN ANNUAL DIABETES RESEARCH CONFERENCE, PRINT INTERVIEWS AND TOLL FREE NUMBER 800-321-3437. THE PUBLIC GAINS KNOWLEDGE ABOUT DIABETES, DIABETES CARE AND RESEARCH TOWARDS FINDING A CURE FOR DIABETES.
THE DIABETES RESEARCH INSTITUTE FOUNDATION FUNDS BASIC, PRE-CLINICAL AND PATIENT-BASED RESEARCH STUDIES, INCLUDING FIVE PHASE I/II CLINICAL STUDIES, SEVERAL OF WHICH ARE SIMULTANEOUSLY UNDERWAY AT THE DIABETES RESEARCH INSTITUTE (DRI), WITH THE OTHERS PENDING COMMENCEMENT. THE ONGOING 'ISLETS IN THE OMENTUM' BIOHUB TRIAL WAS THE FIRST STEP IN TESTING THE SAFETY AND EFFICACY OF INSULIN-PRODUCING CELLS TRANSPLANTED WITHIN A TISSUE-ENGINEERED PLATFORM IN A DIFFERENT SITE THAN THE LIVER, THE TRADITIONAL TRANSPLANT SITE. FOUNDATION FUNDING HAS ALLOWED THE DRI'S CLINICAL CELL TRANSPLANT TEAM TO CONTACT AND SCREEN MORE THAN 1,200 CANDIDATES FOR THIS INNOVATIVE PILOT TRIAL, SEVERAL OF WHOM WERE SELECTED AND PLACED ON THE WAITING LIST TO UNDERGO THE PROCEDURE PENDING THE AVAILABILITY OF A MATCHING DONOR ORGAN. OTHER ALTERNATIVE TRANSPLANT SITES CONTINUE TO BE EXPLORED. DRIF FUNDING ALSO SUPPORTS THE CONTINUED FOLLOW-UP AND CARE OF THE DRI'S ISLET TRANSPLANT PATIENTS WHO HAVE PARTICIPATED IN PREVIOUS CLINICAL TRIALS. MANY OF THESE HAVE REMAINED INSULIN INDEPENDENT FOR A VARYING NUMBER OF YEARS. THIS PAST YEAR, DRI PRESENTED DATA SHOWING THAT THEIR ISLET TRANSPLANT PATIENTS WHO WERE STILL FREE FROM INSULIN FOR AN AVERAGE OF 10 YEARS HAD NEAR-NORMAL BLOOD SUGAR LEVELS, SIMILAR TO THOSE WITHOUT DIABETES. DRIF HAS ALSO FUNDED DRI RESEARCH PROJECTS THAT FOCUS ON ESTABLISHING IMMUNE TOLERANCE AND REVERSING AUTOIMMUNITY, THE BODY'S DESTRUCTION OF THE INSULIN-PRODUCING CELLS WHICH CAUSED THE ONSET OF THE DISEASE. SEVERAL OF THE CLINICAL TRIALS ADDRESS THESE CHALLENGES WHILE OTHER RESEARCH EARLIER IN THE PIPELINE REMAINS UNDERWAY. ANOTHER MAJOR RESEARCH AREA THAT DRIF SUPPORTS IS THE DEVELOPMENT OF AN UNLIMITED SUPPLY OF INSULIN-PRODUCING CELLS. DRIF-FUNDED STUDIES HAVE LED TO SIGNIFICANT PROGRESS IN STIMULATING THE REGENERATION OF PANCREATIC STEM CELLS INTO INSULIN-PRODUCING CELLS USING A SINGLE FDA-APPROVED MOLECULE. THIS SIGNIFICANT FINDING OPENS TO DOOR TO A NATURAL CELL SUPPLY BANK WITHIN THE PATIENT'S BODY, ADDRESSING SEVERAL ONGOING CHALLENGES FOR CURING THE DISEASE. THE DRIF HAS FUNDED INTERNATIONAL RESEARCHER TRAINING AND KEY COLLABORATIVE PROGRAMS THAT HELP ACCELERATE RESEARCH PROGRESS THROUGH THE SHARING OF IDEAS AND ADVANCEMENTS. ALSO, DRIF-FUNDED RESEARCH EQUIPMENT WAS USED IN A PHASE III MULTI-CENTER CLINICAL ISLET TRANSPLANTATION TRIAL. THE RESULTING DATA DEMONSTRATED THAT ISLET TRANSPLANTATION IS EFFECTIVE IN PREVENTING SEVERE HYPOGLYCEMIA - DANGEROUSLY LOW BLOOD SUGAR LEVELS - WHICH REPRESENTS A PARTICULARLY FEARED COMPLICATION IN TYPE 1 DIABETES THAT CAN LEAD TO SEIZURES, LOSS OF CONSCIOUSNESS AND EVEN DEATH. IMPORTANTLY, THE RESULTS OF THIS PHASE III TRIAL PAVE THE WAY FOR ISLET TRANSPLANTATION TO BECOME AN FDA-AUTHORIZED TREATMENT FOR PATIENTS WITH DIABETES AND ONE THAT WOULD BE ELIGIBLE FOR INSURANCE REIMBURSEMENT. KEY FUNDED RESEARCH AREAS INCLUDE CELL-BASED THERAPIES FOR ISLET REPLACEMENT, IMMUNE TOLERANCE, IMMUNE REGULATION, REGENERATIVE MEDICINE, AND STEM CELL RESEARCH, AMONG OTHERS, TO RESTORE BIOLOGICAL INSULIN PRODUCTION. TOGETHER WITH OTHER DIABETES ADVOCACY ORGANIZATIONS, THE DRIF HAS APPEARED BEFORE CONGRESS TO REQUEST INCREASED FUNDING FOR DIABETES RESEARCH, AND HAS MADE RECOMMENDATIONS ON THE FUTURE DIRECTION OF RESEARCH APPROPRIATIONS. DRIF ALSO HOSTS AND PARTICIPATES IN A VARIETY OF INFORMATIONAL WORKSHOPS FOR PEOPLE WITH DIABETES AND THEIR FAMILIES FOCUSING ON THE LATEST ADVANCES TOWARD A CURE AND THE NEWEST DIABETES MANAGEMENT TECHNIQUES. THROUGH ITS WEBSITE DIABETESRESEARCH.ORG, THE DRIF PROVIDES 'NEWS YOU CAN USERESEARCH UPDATES FOR THOSE LIVING WITH DIABETES AND THEIR FAMILY MEMBERS IN THE FORM OF E-NEWSLETTERS, VIDEOS, EMAIL ANNOUNCEMENTS AND INFORMATION VIA SOCIAL MEDIA.
COMMUNITY DIABETES EDUCATION. THE DIABETES RESEARCH INSTITUTE FOUNDATION PROVIDES INFORMATION TO THE PUBLIC VIA ITS WEBSITE LITERATURE, SPEAKERS AND HOSTING AN ANNUAL DIABETES RESEARCH CONFERENCE, PRINT INTERVIEWS AND TOLL FREE NUMBER 800-321-3437. THE PUBLIC GAINS KNOWLEDGE ABOUT DIABETES, DIABETES CARE AND RESEARCH TOWARDS FINDING A CURE FOR DIABETES.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Sean Kramer CEO | 50 | $290,000 | |
Amy Powers Chief Development Officer | 50 | $205,000 | |
Thomas Karlya Senior Vice President | 50 | $200,000 | |
Jill Shapiro Miller Executive Vice President | 50 | $190,000 | |
Tiffany Bedran Chief Adminisrative Officer | 50 | $180,000 | |
Charles Rizzo Director At Large | OfficerTrustee | 5 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
North America's Building Trades Uni Event Planner | 6/29/20 | $275,000 |
Orr Group Inc Fundraising And Mgmt | 6/29/20 | $672,000 |
Aperio Philanthropy Llc Executive Recruiting | 6/29/20 | $325,000 |
Aperio Philanthropy Llc Executive Recruiting | 6/29/20 | $325,000 |
North America's Building Trades Uni Event Planner | 6/29/20 | $275,000 |
Aperio Philanthropy Llc Executive Recruiting | 6/29/20 | $325,000 |
Statement of Revenue | |
---|---|
Federated campaigns | $115,665 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $415,300 |
All other contributions, gifts, grants, and similar amounts not included above | $11,909,453 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $12,440,418 |
Total Program Service Revenue | $0 |
Investment income | $272,180 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $192,642 |
Net Income from Fundraising Events | $969,719 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $13,874,959 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $8,290,523 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $1,157,013 |
Compensation of current officers, directors, key employees. | $287,395 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $1,645,157 |
Pension plan accruals and contributions | $90,653 |
Other employee benefits | $211,506 |
Payroll taxes | $187,519 |
Fees for services: Management | $0 |
Fees for services: Legal | $18,458 |
Fees for services: Accounting | $42,333 |
Fees for services: Lobbying | $4,000 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $0 |
Advertising and promotion | $0 |
Office expenses | $20,503 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $183,938 |
Travel | $0 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $134,740 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $29,582 |
Insurance | $32,252 |
All other expenses | $14,683 |
Total functional expenses | $13,701,622 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $2,173,016 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $7,350,934 |
Accounts receivable, net | $310,952 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Land, buildings, and equipment | $78,137 |
Investments—publicly traded securities | $24,851,115 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $597,652 |
Total assets | $35,361,806 |
Accounts payable and accrued expenses | $846,994 |
Grants payable | $240,224 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $1,087,218 |
Net assets without donor restrictions | $9,463,465 |
Net assets with donor restrictions | $24,811,123 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $35,361,806 |
Over the last fiscal year, we have identified 1 grants that Diabetes Research Institute Foundation Inc has recieved totaling $1,000.
Awarding Organization | Amount |
---|---|
Edge Foundation Inc Vale, NC PURPOSE: OPERATIONS | $1,000 |
Organization Name | Assets | Revenue |
---|---|---|
Parkinsons Foundation Inc Miami, FL | $51,700,116 | $50,273,391 |
The Medical University Of South Carolina Foundation Charleston, SC | $614,746,136 | $28,626,184 |
Delta Health Alliance Inc Stoneville, MS | $28,735,932 | $53,691,246 |
North Carolina Medical Society Foundation Inc Raleigh, NC | $23,889,243 | $25,927,674 |
Max Planck Florida Corporation Jupiter, FL | $113,101,078 | $26,052,125 |
Greenwood Genetic Center Inc Greenwood, SC | $23,474,506 | $25,247,880 |
Bliss Cares Inc Orlando, FL | $24,523,508 | $27,838,732 |
Rheumatology Research Foundation Atlanta, GA | $70,647,398 | $7,906,919 |
Research Triangle Foundation Of North Carolina Research Triangle Park, NC | $210,917,305 | $40,089,804 |
Diabetes Research Institute Foundation Inc Hollywood, FL | $35,361,806 | $13,874,959 |
Memphis Bioworks Foundation Memphis, TN | $6,047,652 | $238,794 |
Foundation For Atlanta Veterans Education And Research Inc Decatur, GA | $10,222,891 | $13,848,947 |